Adoptive immunotherapy with antiviral T cells: Methods and results

Area of Science:

• Immunology
• Transplantation Medicine
• Cell Therapy

Background:

• Viral infections and reactivations are significant causes of morbidity and mortality post-allogeneic haematopoietic progenitor cell transplantation.
• Adoptive immunotherapy with virus-specific T-cells has demonstrated efficacy in treating these viral infections in immunocompromised transplant recipients.

Purpose of the Study:

• To review the evolution of methodologies for producing virus-specific T-cells for therapeutic use.
• To examine the evidence supporting the therapeutic efficacy of these antiviral T-cells.
• To discuss current production platforms and their implications for advanced personalized therapies.

Main Methods:

• Literature review of studies on antiviral T-cell production and efficacy.
• Analysis of current Good Manufacturing Practice (GMP) compliant production platforms.
• Examination of the commercialization and implementation of these platforms.

Main Results:

• The study traces the development of antiviral T-cell production methods.
• Evidence supports the therapeutic efficacy of virus-specific T-cells in transplant patients.
• New automated GMP-compliant platforms are emerging for T-cell therapies.

Conclusions:

• Understanding the production and application of virus-specific T-cells is crucial for their clinical implementation.
• Automated production platforms facilitate the generation of virus-specific T-cells and CAR-T cells under GMP conditions.
• These advancements will improve patient access to novel advanced therapies in the Spanish healthcare system.